论文部分内容阅读
1971年欧洲有四个国家七所医院合作,通过双盲法安慰剂的对照研究提出了子宫β_2受体的拟交感神经药——羟苄麻黄硷(Rito-drine)治疗早产的特异作用的报告。至1979年,世界上已有23个国家将 Ritodrine用于临床有效地治疗早产。1979年美国食品药物摄入咨询委员会(FDA)将 Ritodrine 列为药理学上抑制早产的首选药物。已知,子宫肌上有肾上腺素能神经的α和β受体,刺激α受体可引起子宫张力升高收缩增强;刺激β受体则引起子宫收缩减弱子宫肌弛缓。有人认为β受体兴奋剂的激活腺苷酸环化酶,增加子宫肌细胞内 cAMP 含量,而影响子宫收缩力。同时激活激酶增加
In 1971, seven European hospitals in four countries collaborated to report the specific role of uterine β_2 receptor sympathomimetic drug, Rito-drine, in the treatment of prematurity through a double-blind placebo-controlled study . By 1979, 23 countries in the world have used Ritodrine as a clinically effective treatment for preterm birth. In 1979, the US Food and Drug Administration (FDA) listed Ritodrine as the drug of choice for pharmacological inhibition of preterm birth. It is known that there are adrenergic alpha and beta receptors in the uterine muscle. Stimulation of the alpha receptor causes an increase in contractility of the uterus. Stimulation of the beta receptor causes contraction of the uterus to attenuate uterine muscle relaxation. Some people think that β receptor agonist activation of adenylate cyclase, uterine muscle cells increase cAMP content, and affect uterine contractility. Activation of kinase increased at the same time